Stock listing
NASDAQ:PBLS Parabilis Medicines, Inc. Stock
Home listing (NASDAQ) of Parabilis Medicines, Inc.
Follow Parabilis Medicines, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:PBLS
$27.44 USD -1.03 (-3.6%)
Close on Nov 20, 2026
- Day range
- $26.50 – $28.52 USDNov 20, 2026
- Volume
- 1.25M sharesNov 20, 2026
- Market cap
- $3.39B USDAt the close on Nov 20, 2026 · price × 123.7M shares outstanding
- Traded on an average day
- $30.74M USDMedian day 809,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PBLS · Home | $27.44 USD | -1.03 (-3.6%) | 1,246,548 | $27.09 | $28.52 | $26.50 | $28.47 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PBLS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $27.44 | -1.03 | -3.6% | $27.09 | $28.52 | $26.50 | 1,246,548 | |
| $28.47 | +0.22 | +0.8% | $28.22 | $29.26 | $27.90 | 602,362 | |
| $28.25 | -0.20 | -0.7% | $28.54 | $28.54 | $27.53 | 480,477 | |
| $28.45 | +0.02 | +0.1% | $28.04 | $28.56 | $27.63 | 538,172 | |
| $28.43 | +0.74 | +2.7% | $27.63 | $28.63 | $26.70 | 555,039 | |
| $27.69 | -1.96 | -6.6% | $29.54 | $29.88 | $27.47 | 806,101 | |
| $29.65 | -0.37 | -1.2% | $30.40 | $30.98 | $29.29 | 546,014 | |
| $30.02 | -0.35 | -1.2% | $30.49 | $31.49 | $29.54 | 502,424 | |
| $30.37 | +1.84 | +6.4% | $29.21 | $30.85 | $28.36 | 950,737 | |
| $28.53 | +0.65 | +2.3% | $27.88 | $28.87 | $27.11 | 629,323 | |
| $27.88 | -2.48 | -8.2% | $30.13 | $30.13 | $27.56 | 920,736 | |
| $30.36 | +1.11 | +3.8% | $30.00 | $30.83 | $28.70 | 842,949 | |
| $29.25 | +2.00 | +7.3% | $28.25 | $29.73 | $27.90 | 519,401 | |
| $27.25 | -1.07 | -3.8% | $28.13 | $28.55 | $26.87 | 702,232 | |
| $28.32 | -0.38 | -1.3% | $28.59 | $28.74 | $27.48 | 813,911 | |
| $28.70 | +0.53 | +1.9% | $28.32 | $30.08 | $27.19 | 844,724 | |
| $28.17 | +1.66 | +6.3% | $26.24 | $28.29 | $26.14 | 1,396,094 | |
| $26.51 | +1.48 | +5.9% | $25.00 | $27.20 | $24.75 | 1,572,596 | |
| $25.03 | +0.59 | +2.4% | $25.01 | $25.59 | $23.06 | 1,427,693 | |
| $24.44 | -2.48 | -9.2% | $26.74 | $26.74 | $23.96 | 1,820,900 | |
| $26.92 | -0.93 | -3.3% | $28.03 | $28.29 | $26.58 | 911,900 | |
| $27.85 | +0.77 | +2.8% | $27.39 | $28.48 | $26.40 | 1,392,000 | |
| $27.08 | +1.73 | +6.8% | $25.40 | $27.93 | $24.44 | 1,495,400 | |
| $25.35 | +2.60 | +11.4% | $22.98 | $26.24 | $22.98 | 2,142,600 | |
| $22.75 | -2.43 | -9.7% | $25.39 | $25.71 | $22.66 | 1,115,100 | |
| $25.18 | -0.71 | -2.7% | $25.76 | $26.44 | $24.80 | 955,200 | |
| $25.89 | -0.96 | -3.6% | $27.00 | $27.39 | $25.73 | 764,900 | |
| $26.85 | -2.10 | -7.3% | $29.45 | $29.50 | $26.72 | 1,187,800 | |
| $28.95 | +1.47 | +5.3% | $27.38 | $29.50 | $26.83 | 1,203,000 | |
| $27.48 | -0.61 | -2.2% | $28.15 | $29.50 | $27.21 | 1,086,600 | |
| $28.09 | -0.73 | -2.5% | $28.42 | $28.90 | $26.14 | 1,392,600 | |
| $28.82 | -0.04 | -0.1% | $28.78 | $30.36 | $27.56 | 994,000 | |
| $28.86 | -0.67 | -2.3% | $29.44 | $29.73 | $28.17 | 979,200 | |
| $29.53 | -0.75 | -2.5% | $30.41 | $30.82 | $28.56 | 572,500 | |
| $30.28 | -0.16 | -0.5% | $30.34 | $30.63 | $28.30 | 881,200 | |
| $30.44 | -1.85 | -5.7% | $31.99 | $32.63 | $29.71 | 885,800 | |
| $32.29 | +0.38 | +1.2% | $31.95 | $32.86 | $31.20 | 547,100 | |
| $31.91 | -0.66 | -2.0% | $32.84 | $33.74 | $31.20 | 453,900 | |
| $32.57 | +1.37 | +4.4% | $31.02 | $33.76 | $30.17 | 809,600 | |
| $31.20 | -1.27 | -3.9% | $32.32 | $32.32 | $29.57 | 1,119,000 | |
| $32.47 | -0.84 | -2.5% | $33.32 | $33.73 | $31.06 | 1,165,900 | |
| $33.31 | -4.86 | -12.7% | $37.89 | $37.89 | $32.95 | 1,113,900 | |
| $38.17 | +1.24 | +3.4% | $37.41 | $38.73 | $35.51 | 865,500 | |
| $36.93 | -4.80 | -11.5% | $41.58 | $42.32 | $34.72 | 1,705,600 | |
| $41.73 | +0.85 | +2.1% | $41.01 | $42.49 | $39.41 | 9,086,000 | |
| $40.88 | +4.00 | +10.8% | $37.51 | $42.22 | $37.35 | 1,093,200 | |
| $36.88 | +1.16 | +3.2% | $36.19 | $38.92 | $35.37 | 971,000 | |
| $35.72 | -0.44 | -1.2% | $36.27 | $36.38 | $35.24 | 446,200 | |
| $36.16 | -0.72 | -2.0% | $37.06 | $37.58 | $35.60 | 482,300 | |
| $36.88 | +0.56 | +1.5% | $36.90 | $37.74 | $36.44 | 364,800 | |
| $36.32 | -2.44 | -6.3% | $38.76 | $38.77 | $36.13 | 680,800 | |
| $38.76 | -1.01 | -2.5% | $39.77 | $40.13 | $38.33 | 501,200 | |
| $39.77 | -0.65 | -1.6% | $40.97 | $41.05 | $39.07 | 564,000 | |
| $40.42 | -0.33 | -0.8% | $40.20 | $41.19 | $39.50 | 380,700 | |
| $40.75 | +0.64 | +1.6% | $40.21 | $40.83 | $39.12 | 408,300 | |
| $40.11 | +0.64 | +1.6% | $39.73 | $41.14 | $38.31 | 363,900 | |
| $39.47 | +0.46 | +1.2% | $39.15 | $40.00 | $37.88 | 500,200 | |
| $39.01 | -0.10 | -0.3% | $39.08 | $40.01 | $37.77 | 529,900 | |
| $39.11 | -0.18 | -0.5% | $38.96 | $40.02 | $38.50 | 316,200 | |
| $39.29 | +0.03 | +0.1% | $39.00 | $40.19 | $38.22 | 445,400 | |
| $39.26 | +0.03 | +0.1% | $39.17 | $39.41 | $38.09 | 409,100 | |
| $39.23 | +0.80 | +2.1% | $38.52 | $39.90 | $38.37 | 286,098 | |
| $38.43 | -0.93 | -2.4% | $39.42 | $40.56 | $38.00 | 340,272 | |
| $39.36 | -0.22 | -0.6% | $39.41 | $40.92 | $38.95 | 354,600 | |
| $39.58 | -1.74 | -4.2% | $40.70 | $41.49 | $39.31 | 205,800 |
- Ticker
- NASDAQ:PBLS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 32 slides
Latest news
Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates
Nov 12, 2026
Closed $27.69 (-6.6%) on Nov 12, 2026
Parabilis Medicines to Participate in Upcoming November Investor Conferences
Nov 3, 2026
Closed $29.25 (+7.3%) on Nov 3, 2026
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
Oct 24, 2026
Closed $25.03 (+2.4%) on Oct 26, 2026
Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026
Oct 19, 2026
Closed $25.35 (+11.4%) on Oct 19, 2026
Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
Oct 14, 2026
Closed $25.89 (-3.6%) on Oct 14, 2026
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Sep 1, 2026
Closed $39.47 (+1.2%) on Sep 1, 2026
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
Aug 25, 2026
Closed $39.23 (+2.1%) on Aug 25, 2026
Parabilis Medicines, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 8 in the last 12 months · 8 in all · newest Nov 12, 2026 · oldest 2026
- Decks
- 3 decks · latest September 2026
Where Parabilis Medicines, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PBLS · Home listing · This page | NASDAQ | United States | USD |
| BOATS:PBLS | BOATS | United States | USD |
Valuation
Price/book 3.4× against a median of 4.1×: 4th lowest of 11 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.53B USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- Under 6 months of closes
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Parabilis Medicines, Inc. · NASDAQ:PBLS | US$3.39B | US$2.53B | n/a | n/a | n/a | 3.4× | n/a | 0.0× | n/a |
| Xenon Pharmaceuticals Inc. · NASDAQ:XENE | US$3.64B | US$2.70B | n/a | n/a | n/a | 3.2× | n/a | 0.0× | 0.80 |
| Relay Therapeutics, Inc. · NASDAQ:RLAY | US$3.56B | US$2.74B | n/a | 265× | n/a | 4.3× | n/a | 0.0× | 1.48 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A · SSE:688336 | US$3.56B | US$3.42B | 7.6× | 5.1× | n/a | 2.7× | 69.9% | 0.0× | n/a |
| Enliven Therapeutics, Inc. · NASDAQ:ELVN | US$3.42B | US$2.54B | n/a | n/a | n/a | 3.9× | n/a | 0.0× | 0.89 |
| Disc Medicine, Inc. · NASDAQ:IRON | US$3.42B | US$2.80B | n/a | n/a | n/a | 5.7× | n/a | 0.1× | 0.94 |
| Viridian Therapeutics, Inc. · NASDAQ:VRDN | US$3.40B | US$2.69B | n/a | 102× | n/a | 5.9× | n/a | 0.4× | 1.00 |
| Caliway Biopharmaceuticals Co Ltd · TWSE:6919 | US$3.38B | US$3.27B | n/a | n/a | n/a | 12.7× | n/a | 0.0× | n/a |
| Amylyx Pharmaceuticals, Inc. · NASDAQ:AMLX | US$3.35B | US$2.58B | n/a | n/a | n/a | 4.4× | n/a | 0.0× | 1.21 |
| Iovance Biotherapeutics, Inc. · NASDAQ:IOVA | US$3.19B | US$2.86B | n/a | 7.5× | n/a | 3.9× | −58.2% | 0.1× | 1.62 |
| AbCellera Biologics Inc. · NASDAQ:ABCL | US$3.16B | US$2.53B | n/a | 37.3× | n/a | 3.0× | −218.5% | 0.1× | 2.42 |
| Median of the others | US$3.41B | US$2.72B | 7.6× | 37.3× | 4.1× | −58.2% | 0.0× | 1.11 |
Forecasts
7 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 41.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.42 · 2 analysts
- Revenue, year to Dec 2026
- 979.2K · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Mathai Mammen | Chairman, CEO and President |
| Thomas Kotarakos | Chief Financial Officer |
| Alan M. Sebulsky | President, Apothecary Capital Management, Inc |
| Teresa Jurgensen | Executive Vice President, General Counsel |
| John McGee | Scientific Co-Founder and Executive Vice President, Head of Platform |
| Jonathan Hurov | Executive Vice President, Discovery Biology |
| Marie Nguyen | Senior Vice President, Head of Clinical Development |
| Markus Haeberlein | Executive Vice President, Discovery Science |
| Sheryl Jacobs | Senior Vice President, Development Operations |
| Hannah Walter | Enterprise Strategic Operations, Chief of Staff to the CEO |
| Helen Ho | Chief Business and Strategy Officer |
| Kristen Stants | Chief People Officer |
| Rick Klausner | Founder and Chief Scientist Altos Labs, Inc. |
| Rohin Mhatre | Chief Technical Operations Officer |
Board
| Director | Role |
|---|---|
| Alexis Borisy | Lead Independent Director; Chairman, Nextech Invest; Chairman, Curie.Bio |
| Mathai Mammen | Chairman, CEO and President |
| Craig L. Tendler | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −6.6% |
| Q2 2026 | Aug 13, 2026 · Before open | −4.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 32 slides | September 2026 |
| Earnings Presentation (August 2026) | Earnings | 32 slides | Aug 13, 2026 |
| Technical Presentation (October 2025) | Technical | 17 slides | October 2025 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$770.5M raised · US$20 a share · Leerink Partners +4 Dealers: Leerink Partners (co-lead), BofA Securities (co-lead), Evercore ISI (co-lead), Guggenheim Securities (co-lead), LifeSci Capital | Jun 11, 2026 |
| Private placement of common stock Closed: US$75M raised · US$18 a share Buyers: Regeneron Pharmaceuticals, Inc. (4,166,666 shares of common stock at $18.00 per share) | Jun 11, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$20.00 a share on Jun 9, 2026.
- Price
- US$20.00 a share
- Shares offered
- 33,500,000 shares of common stock
- Offering size
- US$670 million
- Underwriters' option
- Up to 5,025,000 more shares
- Listing
- PBLS on the Nasdaq Global Select Market
- Underwriters
- Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities, LifeSci Capital · In the order on the cover
- Shares delivered
- On or about Jun 11, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 2, 2026 |
| Filed publicly | May 19, 2026 |
| Amended 3 times | Newest Jun 9, 2026 |
| Shares registered with an exchange | Jun 5, 2026 |
| Declared effective by the SEC | Jun 9, 2026 |
| Final prospectus, with the price | Jun 10, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 10, 2026 |
| FWP · Free writing prospectus | Jun 10, 2026 |
| EFFECT · Notice that a registration is effective | Jun 9, 2026 |
| S-1MEF · Registration of more shares for the same offering | Jun 9, 2026 |
| CERT · Exchange's certificate of listing | Jun 9, 2026 |
| S-1/A · Registration statement, amended | Jun 9, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 5, 2026 |
| S-1/A · Registration statement, amended | Jun 4, 2026 |
| S-1/A · Registration statement, amended | May 27, 2026 |
| S-1 · Registration statement | May 19, 2026 |
All 11 filings
| Filing | Filed |
|---|---|
| DRS · Draft registration statement | Apr 2, 2026 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 10, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | 0 | 0 |
| Research and development | 125.6M | 100.8M |
| Selling, general and administrative | 26.5M | 25.3M |
| Operating income | -152.1M | -126.1M |
| Depreciation and amortization | 2.50M | 2.10M |
| EBITDA | -149.6M | -124.0M |
| Interest expense | 1.52M | 1.49M |
| Income before tax | -145.9M | -117.9M |
| Net income | -145.9M | -117.9M |
| Earnings per share, basic | -1.23 | -1.00 |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 27.7M | 47.3M |
| Short-term investments | 0 | 40.7M |
| Receivables | 360.0K | |
| Current assets | 29.4M | 92.2M |
| Total assets | 80.8M | 149.3M |
| Accounts payable | 17.3M | 9.51M |
| Current liabilities | 56.8M | 32.4M |
| Long-term debt | 12.8M | |
| Total debt | 58.7M | 66.2M |
| Total liabilities | 97.3M | 92.8M |
| Shareholders' equity | -16.5M | 56.4M |
| Shares outstanding | 118.1M | 118.1M |
Cash flow
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash from operations | -123.7M | -103.6M |
| Capital spending | -306.0K | -879.0K |
| Free cash flow | -124.0M | -104.5M |
| Cash from investing | 39.8M | 30.2M |
| Cash from financing | 64.4M | 78.1M |
| Share buybacks | -62.0K | -494.0K |
| Change in cash | -19.6M | 4.70M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 8-K · Current report | Nov 5, 2026 | Material contract | SEC |
| 8-K · Current report | Sep 15, 2026 | Current report | SEC |
| 8-K · Current report | Sep 2, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 25, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 25, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
All 65 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 29, 2026 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Jun 18, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2026 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Jun 10, 2026 | Offer document | SEC |
| 424B4 · Prospectus | Jun 10, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 10, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Jun 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 9, 2026 | Insider trade | SEC |
| FWP · Free writing prospectus | Jun 9, 2026 | Offer document | SEC |
| S-1MEF · Registration of more shares for the same offering | Jun 9, 2026 | Offer document | SEC |
| CERT · Exchange's certificate of listing | Jun 9, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jun 9, 2026 | Offer document | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Jun 5, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jun 4, 2026 | Offer document | SEC |
| S-1/A · Registration statement, amended | May 27, 2026 | Offer document | SEC |
| S-1 · Registration statement | May 19, 2026 | Offer document | SEC |
| DRS · Draft registration statement | Apr 2, 2026 | Offer document | SEC |
| D | Dec 2, 2022 | Other filings | SEC |
| D | Jan 5, 2021 | Other filings | SEC |
| D/A | May 16, 2018 | Other filings | SEC |
| D | Feb 14, 2018 | Other filings | SEC |
| D/A | Aug 22, 2017 | Other filings | SEC |
| D | Jun 7, 2016 | Other filings | SEC |
| D | Nov 13, 2015 | Other filings | SEC |
Cap table
Built by 6ix from Parabilis Medicines, Inc.’s releases · as of Jun 11, 2026
- Common shares
- 123,676,615
- Fully diluted
- 123,676,615
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 123,676,615 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 123,676,615 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Rajeev M Shah Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past) | Director · Since at least Jun 9, 2026 |
| Alexis Borisy Other companies: Revolution Medicines, Inc. (Director · Since at least Jun 26, 2025); Blueprint Medicines Corp (Director · Since at least Jun 18, 2025); Relay Therapeutics, Inc. (Director · Since at least Jun 6, 2025); Tango Therapeutics, Inc. (Director · Since at least Jun 5, 2025) | Lead Independent Director; Chairman, Nextech Invest; Chairman, Curie.Bio · Since at least Jun 9, 2026 |
| Barbara Weber Other companies: Tango Therapeutics, Inc. (Director, Executive Chair, Director · Since at least Aug 10, 2021); OPY Acquisition I Corp (Director · Oct 26, 2021 – Oct 26, 2021 · Past); Revolution Medicines, Inc. (Director · Feb 12, 2020 – Oct 8, 2024 · Past) | Director · Since at least Jun 9, 2026 |
| Krishna Yeshwant Other companies: Verve Therapeutics Inc (Director · Since at least Jun 16, 2021); EQRx Inc (Director · Dec 17, 2021 – Nov 9, 2023 · Past); Foundation Medicine Inc (Director · Jun 16, 2016 – Jul 31, 2018 · Past) | Director · Since at least Jun 9, 2026 |
| Craig L. Tendler Other companies: TuHURA Biosciences, Inc. (Director · Since at least Mar 10, 2025) | Director · Since at least Aug 22, 2026 |
| Richard Klausner Other companies: Lyell Immunopharma, Inc. (Director · Since at least Jun 8, 2021) | Director · Since at least Jun 9, 2026 |
| Rick Klausner Other companies: Lyell Immunopharma, Inc. (Founder & Chairman of the Board · Since at least Jun 9, 2025) | Founder and Chief Scientist Altos Labs, Inc. · Since at least Nov 4, 2026 |
| Alan M. Sebulsky | President, Apothecary Capital Management, Inc · Since at least Jun 16, 2026 |
| Edward M Fitzgerald | Director · Since at least Jun 11, 2026 |
| Hannah Walter | Enterprise Strategic Operations, Chief of Staff to the CEO · Since at least Nov 4, 2026 |
All 21 people
| Person | Seat |
|---|---|
| Helen Ho | Chief Business and Strategy Officer · Since at least Jun 9, 2026 |
| John McGee | Scientific Co-Founder and Executive Vice President, Head of Platform · Since at least Nov 4, 2026 |
| Jonathan Hurov | Executive Vice President, Discovery Biology · Since at least Nov 4, 2026 |
| Kristen Stants | Chief People Officer · Since at least Nov 4, 2026 |
| Marie Nguyen | Senior Vice President, Head of Clinical Development · Since at least Nov 4, 2026 |
| Markus Haeberlein | Executive Vice President, Discovery Science · Since at least Nov 4, 2026 |
| Mathai Mammen | Chairman, CEO and President · Since at least Nov 3, 2026 |
| Rohin Mhatre | Chief Technical Operations Officer · Since at least Nov 4, 2026 |
| Sheryl Jacobs | Senior Vice President, Development Operations · Since at least Nov 4, 2026 |
| Teresa Jurgensen | Executive Vice President, General Counsel · Since at least Nov 4, 2026 |
| Thomas Kotarakos | Chief Financial Officer · Since at least Jun 9, 2026 |
Log in to ask 6ix AI your own questions about Parabilis Medicines, Inc.